AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Anti-idiotypic vaccine successful in treating non-Hodgkin lymphoma.(Brief Article)
2002 JUL 24 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - The idiotypic proteins expressed by an individual's tumor cells can be used in a vaccine to stimulate a specific immune response against the tumor. Investigators in Spain used this approach successfully to treat patients with non-Hodgkin lymphoma.
Active immunotherapy uses the particular Ig protein expressed by a tumor to provoke the immune system to mount a focused response against the tumor. Investigators are testing the feasibility and effectiveness of this approach in a clinical setting, including Y. Barrios and colleagues at the Clinica Puerta de Hierro in Madrid who tested the method in nine patients with follicular non-Hodgkin low-grade B-cell lymphoma (NHL).
Barrios and associates obtained the idiotypic proteins of each patient's tumor cells by somatic fusion of the cells. The researchers then prepared a vaccine composed of their specific tumor Ig protein conjugated to keyhole limpet hemocyanine. After vaccination, measurements of anti-idiotypic immune response and circulating t(14:18)[superscript]+ tumor cells were obtained, and the patients were evaluated for toxic response and clinical outcome (Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma, Haematologica, 2002;87(4):400-407).
Follow-up occurred 10-64 months (median 40) after the start of immunotherapy.
Tumors did not progress in any of the patients, and two of the nine ...
- Biomira Receives Further U.S. Patent Protection For Its Idiotypic Vaccine...
- Press release article from: PR Newswire November 9, 2001 700+ words
EDMONTON, Nov. 9 /PRNewswire/ - Biomira Inc. (Nasdaq: BIOM) (TSE: BRA) announced today that its subsidiary, Biomira USA Inc., was issued a second patent this year from the U.S. Patent and Trademark Office for composition of matter used in Biomira's cancer vaccine program. The issued patent, number
- PRESS RELEASE: Biomira receives further US patent protection for its idiotypic...
- News wire article from: Chemical Business Newsbase November 15, 2001 700+ words
Biomira Inc announced that its subsidiary, Biomira USA Inc, was issued a second patent during 2001 from the US Patent and Trademark Office for composition of matter used in Biomira's cancer vaccine programme. The issued patent, number 6,312,718, is entitled "Vaccine for B-cell Malignancies", and is
- Association between Epstein-Barr virus and classic Hodgkin lymphoma in Jordan:...
- Magazine article from: Southern Medical Journal Vasef, Mohammad A. Ubaidat, Manaf A. Khalidi, Hasan S. Almasri, Nidal M. Al-Abbadi, Mousa Annab, Hassan Z. March 1, 2004 700+ words
...association between Epstein-Barr virus and Hodgkin lymphoma has been shown in several parts of...incidence of Epstein-Barr virus in Hodgkin lymphoma varies significantly from one country...protein, we analyzed 28 cases of Hodgkin lymphoma from Jordan and 30 cases from the...
- Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at...
- Press release article from: Business Wire June 5, 2008 700+ words
...relapsed or refractory non-Hodgkin lymphoma. SGN-40 is a humanized...most common type of non-Hodgkin lymphoma." SGN-40 Phase I Study...Fifty patients with non-Hodgkin lymphoma were treated on the open...
- Seattle Genetics Receives Special Protocol Assessment for SGN-35 Pivotal Trial...
- Press release article from: Business Wire January 21, 2009 700+ words
Initiation of clinical trials for Hodgkin lymphoma and ALCL planned in first quarter...patients with relapsed or refractory Hodgkin lymphoma. The SPA provides an agreement between...patients with relapsed or refractory Hodgkin lymphoma who previously received autologous...
- Research on non-hodgkin lymphoma detailed by C. Chao and co-authors.
- Newspaper article from: Blood Weekly October 16, 2008 700+ words
...implicated in the pathogenesis of non-Hodgkin lymphoma," scientists writing in the American...Epidemiology report (see also Non-Hodgkin Lymphoma). "The authors performed a systematic...diabetes mellitus and risk of non-Hodgkin lymphoma. Ten case-control studies and three...
- Non-Hodgkin lymphoma: another cancer may be linked to diet. (adapted from the...
- Newspaper article from: HealthFacts May 1, 1996 700+ words
Non-Hodgkin lymphoma, a cancer of the lymph nodes...the study, 104 developed non-Hodgkin lymphoma. Brian Chiu, M.S., University...higher the risk of developing non-Hodgkin lymphoma. The researchers say that their...
- Seattle Genetics Initiates Pivotal Trial of SGN-35 for Hodgkin Lymphoma.
- Newspaper article from: Blood Weekly March 5, 2009 700+ words
...patients with relapsed or refractory Hodgkin lymphoma. The trial is being conducted under...toward bringing this promising ADC to Hodgkin lymphoma patients in need of new and better...patients with relapsed or refractory Hodgkin lymphoma who previously received autologous...
- Hodgkin lymphoma in a renal transplant recipient associated with low peripheral...
- Magazine article from: Archives of Pathology & Laboratory Medicine Craver, Randall D. Scheer, Douglas Correa, Hernan Vehaskari, V. Matti Yu, Lolie C. November 1, 2001 700+ words
Hodgkin lymphoma, although one of the more frequent...lymphoproliferative disorders and Hodgkin lymphoma. Epstein-Barr virus posttransplant...of patients with EBV associated Hodgkin lymphoma, (2) there are no reports quantitating...
- New non-hodgkin lymphoma risk factors study findings have been published by...
- Newspaper article from: Blood Weekly December 25, 2008 700+ words
...cohort of elderly patients with non-Hodgkin lymphoma' new findings in non-hodgkin lymphoma. According to a study from the United...in survival among patients with non-Hodgkin lymphoma (NHL), although these disparities...
Source: HighBeam Research, Anti-idiotypic vaccine successful in treating non-Hodgkin...